Elevated VCAM-1 levels in peripheral blood are associated with brain structural and functional alterations in major depressive disorder. 2024

Jingjing Zhou, and Rui Liu, and Jia Zhou, and Jing Liu, and Yuan Zhou, and Jian Yang, and Gang Wang
The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital & the Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.

BACKGROUND Vascular cell adhesion molecule-1 (VCAM-1) is a well-known biomarker of endothelial activation. This study aimed to determine whether changes in peripheral VCAM-1 levels occurred in major depressive disorder (MDD) patients and explored immune-brain interactions based on neuroimaging. METHODS This study included 165 subjects (80 healthy controls [HCs] and 85 MDD patients). Of them, 133 underwent magnetic resonance imaging. VCAM-1 was measured using a commercially available Enzyme-Linked Immunosorbent Assay kit following the manufacturer's instructions. The gray matter volume (GMV) and surface-based functional connectivity (FC) were calculated based on Schaefer parcellation 400 parcels. RESULTS Compared with the HCs, MDD patients exhibited significantly higher level of VCAM-1. The correlation analysis showed that VCAM-1 had a significant negative correlation with GMV of the right medial frontal cortex (MFC) and postcentral (PostCG). The mediation analyses showed that VCAM-1 mediated the association between group and GMV of PostCG and the FC of left ventral prefrontal cortex (vPFC) with right inferior parietal lobe (IPL). CONCLUSIONS This study showed that a high level of VCAM-1 was associated to the decreased GMV in the right MFC and PostCG, and mediated the FC of the left vPFC with right IPL. These findings suggested that VCAM-1 might contribute to the etiology of MDD by influencing brain structure and function. CONCLUSIONS The cross-sectional design makes it difficult to determine the causal relationship and dynamic effect among VCAM-1, brain structure/function features, and depressive symptoms.

UI MeSH Term Description Entries

Related Publications

Jingjing Zhou, and Rui Liu, and Jia Zhou, and Jing Liu, and Yuan Zhou, and Jian Yang, and Gang Wang
January 2018, Neuropsychiatric disease and treatment,
Jingjing Zhou, and Rui Liu, and Jia Zhou, and Jing Liu, and Yuan Zhou, and Jian Yang, and Gang Wang
January 2023, Clinical pathology (Thousand Oaks, Ventura County, Calif.),
Jingjing Zhou, and Rui Liu, and Jia Zhou, and Jing Liu, and Yuan Zhou, and Jian Yang, and Gang Wang
November 2022, Journal of basic and clinical physiology and pharmacology,
Jingjing Zhou, and Rui Liu, and Jia Zhou, and Jing Liu, and Yuan Zhou, and Jian Yang, and Gang Wang
May 2017, Comprehensive psychiatry,
Jingjing Zhou, and Rui Liu, and Jia Zhou, and Jing Liu, and Yuan Zhou, and Jian Yang, and Gang Wang
January 2020, Frontiers in neuroscience,
Jingjing Zhou, and Rui Liu, and Jia Zhou, and Jing Liu, and Yuan Zhou, and Jian Yang, and Gang Wang
February 2023, Psychological medicine,
Jingjing Zhou, and Rui Liu, and Jia Zhou, and Jing Liu, and Yuan Zhou, and Jian Yang, and Gang Wang
August 2011, Brain, behavior, and immunity,
Jingjing Zhou, and Rui Liu, and Jia Zhou, and Jing Liu, and Yuan Zhou, and Jian Yang, and Gang Wang
June 2019, Journal of affective disorders,
Jingjing Zhou, and Rui Liu, and Jia Zhou, and Jing Liu, and Yuan Zhou, and Jian Yang, and Gang Wang
January 2023, Clinical pathology (Thousand Oaks, Ventura County, Calif.),
Jingjing Zhou, and Rui Liu, and Jia Zhou, and Jing Liu, and Yuan Zhou, and Jian Yang, and Gang Wang
January 2022, NeuroImage. Clinical,
Copied contents to your clipboard!